BMC Cancer (Sep 2024)

Multi‑omics identification of a signature based on malignant cell-associated ligand–receptor genes for lung adenocarcinoma

  • Shengshan Xu,
  • Xiguang Chen,
  • Haoxuan Ying,
  • Jiarong Chen,
  • Min Ye,
  • Zhichao Lin,
  • Xin Zhang,
  • Tao Shen,
  • Zumei Li,
  • Youbin Zheng,
  • Dongxi Zhang,
  • Yongwen Ke,
  • Zhuowen Chen,
  • Zhuming Lu

DOI
https://doi.org/10.1186/s12885-024-12911-5
Journal volume & issue
Vol. 24, no. 1
pp. 1 – 21

Abstract

Read online

Abstract Purpose Lung adenocarcinoma (LUAD) significantly contributes to cancer-related mortality worldwide. The heterogeneity of the tumor immune microenvironment in LUAD results in varied prognoses and responses to immunotherapy among patients. Consequently, a clinical stratification algorithm is necessary and inevitable to effectively differentiate molecular features and tumor microenvironments, facilitating personalized treatment approaches. Methods We constructed a comprehensive single-cell transcriptional atlas using single-cell RNA sequencing data to reveal the cellular diversity of malignant epithelial cells of LUAD and identified a novel signature through a computational framework coupled with 10 machine learning algorithms. Our study further investigates the immunological characteristics and therapeutic responses associated with this prognostic signature and validates the predictive efficacy of the model across multiple independent cohorts. Results We developed a six-gene prognostic model (MYO1E, FEN1, NMI, ZNF506, ALDOA, and MLLT6) using the TCGA-LUAD dataset, categorizing patients into high- and low-risk groups. This model demonstrates robust performance in predicting survival across various LUAD cohorts. We observed distinct molecular patterns and biological processes in different risk groups. Additionally, analysis of two immunotherapy cohorts (N = 317) showed that patients with a high-risk signature responded more favorably to immunotherapy compared to those in the low-risk group. Experimental validation further confirmed that MYO1E enhances the proliferation and migration of LUAD cells. Conclusion We have identified malignant cell-associated ligand–receptor subtypes in LUAD cells and developed a robust prognostic signature by thoroughly analyzing genomic, transcriptomic, and immunologic data. This study presents a novel method to assess the prognosis of patients with LUAD and provides insights into developing more effective immunotherapies.

Keywords